je.st
news
Tag: studies
Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting
2015-11-16 14:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the companys C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens a regimen of grazoprevir1, MK-36822 and elbasvir3; and a regimen of grazoprevir, MK-3682 and MK-84084 in treatment-nave patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
results
studies
meeting
GlaxoSmithKline plans to seek approval for up to 20 new drugs by 2020, start studies on others
2015-11-04 04:50:02| Biotech - Topix.net
GlaxoSmithKline could seek regulatory approval for up to 20 new medicines before 2020 and some could hit the market by then, enabling it to boost revenue rather than just compensate for declining sales of its older drugs. The British drugmaker said it could start late-stage patient testing in the next two years on about 20 new drugs or new uses for existing ones.
Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event
2015-11-03 04:51:04| drugdiscoveryonline Home Page
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, recently announced the phase 3 clinical trial designs for the luspatercept program in myelodysplastic syndromes (“MEDALIST” study) and beta-thalassemia (“BELIEVE” study), phase 1 preliminary results from the ACE-083 program, and its new IntelliTrapdrug discovery platform
Tags: day
results
research
development
SAES studies the variations of underwater ambient noise in the Mediterranean
2015-10-27 18:30:00| Naval Technology
SAES has presented its latest study on noise pollution in the marine environment within the Spanish Congress of Acoustics 'TecniAcústica 2015', held in Valencia and organised by the Spanish Association of Acoustics (SAE).
Tags: the
studies
noise
variations
Univ of Utah studies find up to 27 seconds of mental distraction for drivers after using new hands-free technologies
2015-10-23 15:55:24| Green Car Congress
Sites : [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] next »